No single ticker was named. Biotech ETFs are one way for retail investors to get exposure. Not a recommendation.
XBI favored over IBB for biotech M&A play
The case was made that the XBI small-cap biotech ETF will benefit more from expected M&A activity than the larger-cap IBB, due to pharma's need to acquire smaller companies.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.